Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Jerusalem

Showing results (81-90 of 89) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 89 results.
Breast Cancer Research : BCR|August 31, 2023
Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrantP Neven, P A Fasching, S Chia, et al.
ESMO Open|January 21, 2023
Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trialE de Azambuja, E Agostinetto, M Procter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 20, 2021
Corrigendum to 'Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival': [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024]D J Slamon, P Neven, S Chia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 12, 2017
A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trialA Gennari, Z Sun, U Hasler-Strub, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 8, 2021
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survivalD J Slamon, P Neven, S Chia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 16, 2018
Adherence to geriatric assessment-based recommendations in older patients with cancer: a multicenter prospective cohort study in BelgiumC Kenis, L Decoster, J Flamaing, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|December 5, 2018
Determining clinically important differences in health-related quality of life in older patients with cancer undergoing chemotherapy or surgeryC Quinten, C Kenis, L Decoster, et al.
The Journal of Nutrition, Health & Aging|January 6, 2016
A Belgian Survey on Geriatric Assessment in Oncology Focusing on Large-Scale Implementation and Related Barriers and FacilitatorsC Kenis, P Heeren, L Decoster, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 13, 2021
Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen SubstudyG Jerusalem, S Farah, A Courtois, et al.
Pageof 9

Showing results (81-90 of 89) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 89 results.
Breast Cancer Research : BCR|August 31, 2023
Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrantP Neven, P A Fasching, S Chia, et al.
ESMO Open|January 21, 2023
Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trialE de Azambuja, E Agostinetto, M Procter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 20, 2021
Corrigendum to 'Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival': [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024]D J Slamon, P Neven, S Chia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 12, 2017
A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trialA Gennari, Z Sun, U Hasler-Strub, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 8, 2021
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survivalD J Slamon, P Neven, S Chia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 16, 2018
Adherence to geriatric assessment-based recommendations in older patients with cancer: a multicenter prospective cohort study in BelgiumC Kenis, L Decoster, J Flamaing, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|December 5, 2018
Determining clinically important differences in health-related quality of life in older patients with cancer undergoing chemotherapy or surgeryC Quinten, C Kenis, L Decoster, et al.
The Journal of Nutrition, Health & Aging|January 6, 2016
A Belgian Survey on Geriatric Assessment in Oncology Focusing on Large-Scale Implementation and Related Barriers and FacilitatorsC Kenis, P Heeren, L Decoster, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 13, 2021
Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen SubstudyG Jerusalem, S Farah, A Courtois, et al.
Pageof 9